摘要
目的:分析国家药品集中采购中标企业规模结构,为国家集采常态化制度化推进和医药产业可持续化发展提供政策建议。方法:采用国家医疗保障局官网中标数据及《中国医药统计年报2018》数据分析结合企业负责人深入访谈。结果:中选品种数和投标企业中标率均呈上升的趋势,五批集采中标企业排名与中标产品分布呈现“盆地”效应。结论:国家药品集中采购对药品市场影响加深;中尾部企业面临供应与成本的双重压力;谨防供应成本压力向质量管理体系传导;持续促进药品市场的可持续良性发展。
Objective:To analyze the scale and structure of bid-winning enterprises in national volume-based procurement,and provide policy suggestions for the normalization and institutionalization of national centralized drug procurement and sustainable development of pharmaceutical industry.Methods:The bid-winning results were analyzed using the data from the official website of National Healthcare Security Administration and the data from the 2018 China Pharmaceutical Statistical Annual Report and in-depth interviews with enterprise leaders.Results:The number of selected varieties and the winning rate of the bidding enterprises showed an increasing trend.The ranking of the winning enterprises and the distribution of the winning products in these five batches of collective mining showed a "basin" effect.Conclusion:The influence of national volume-based procurement on drug market is deepening.Middle and tail enterprises faced double pressure of supply and cost.It is needed to beware of supply cost pressure to the quality management system transmission,and continue to promote the sustainable and benign development of the pharmaceutical market.
作者
陈珉惺
徐源
何江江
宋捷
金春林
CHEN Min-xing;XU Yuan;HE Jiang-jiang(Shanghai Health Development Research Center,Shanghai Medical Information Center,Shanghai,200031,China;不详)
出处
《中国卫生经济》
北大核心
2022年第4期67-69,共3页
Chinese Health Economics
关键词
国家药品集中采购
带量采购
企业规模
national pharmacy centralized drug procurement
volume-based procurement
enterprise scale
